UK markets closed

Zogenix, Inc. (ZGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.43-0.13 (-0.60%)
At close: 4:00PM EST

21.43 0.00 (0.00%)
After hours: 5:16PM EST

Sign in to post a message.
  • l
    louis
    Zogenix shares are up 6.06% this morning. They are projected to report quarterly loss at $0.98 per share on revenue of $2.51 million.
  • S
    SAN
    A good company is what creates a value for you. Zogenix has the institution holding, has a good record but recent evaporation of its stock price has eroded all investors confidence. The bottom line is no matter how ambitious or pipeline is, it has to have the resilience.There are too many companies, on the other hand, like $6 but they haven’t dipped as much. People who invested with a lot of trust in this, see they being deceived. Hope somewhere the management sees this post to understand this sooner to curb this falling knife. I am sure patience has its limits and no matter what you do after a certain threshold things never come back or in the best case takes years. So Zogenix has to show the resilience and management has to work hard in either buying back or other capabilities to bring back the investor confidence. I can’t stress more on that.
  • D
    David
    EMA APPROVAL!
  • M
    Mr. Clean
    Oh we got some good news!
  • B
    BigDaddyLongNuts
    And this stock is still undervalued. Get in now before it takes off
  • f
    fred
    No bump from the WMS data presentation.@&@&$&@:
  • S
    SAN
    Institutional buying has been active but the share price has been going down for past several weeks.How is that happening is what I am trying to understand. Can some one who is long, chime in please on the prospects of this. Thanks in advance.
  • D
    David
    World Muscle Society 2020 Congress presentation tomorrow, Thu, 5:30pm, 10/1, on MT1621 TK2 deficiency drug update. The Congress is all virtual. Wall Street is following closely. Look for good press Fri or next week.
  • M
    Mr. Clean
    Company could care less about its shareholders
  • 💊C
    The offering is more bond-like w a great 2.75% rate, but there is probably a future dilute coming. Q3 earnings may disappoint due to timing of the raise so hold on tight.
  • M
    Mr. Clean
    Buyout coming
  • S
    SAN
    Pattern recognition: it will be stable for few days and all of a sudden drop drastically, locking in investors at lower levels. It dropped from $53 to 45 to 24 to 18. If you look at the graphs, it was $4 lower yesterday but never went up unlike other stocks and remained at that level only. Today, it has been hovering around 17.45.
  • w
    wanderley
    52 week low is coming
  • D
    David
    Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet...
    Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet...
    www.globenewswire.com
  • 💊C
    Zogenix passed 3rd P3 trial in Dravet w usual 65% adjusted reduction. This one enables them to submit NDA in Japan.
  • j
    jung
    I was looking to bottomfishing today but I just saw a block sale of almost 7mil shares @$17,55. I'm not sure if it's a good sign or a bad one so I cancelled my buy order.
  • D
    David
    Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
    Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
    seekingalpha.com
  • D
    David
    Mizuho Securities’ Difei Yang also reiterated her bullish perspective on the stock saying “We note that this is a broader patient designation than the Phase 3 trial, which consisted of subjects age 2-18.” The analyst points out that the labeling includes a boxed warning which states that Fintepla is associated with valvular heart disease (VHD) and pulmonary arterial hypertension (PAH)- but says that this is also ‘as expected’.

    Yang already had a 100% probability of success on the indication and so reaffirmed her buy rating and $64 price target. This suggests shares can more than double from current levels.
  • H
    Heather
    The FDA’s approval was based on data from two placebo-controlled phase III studies and safety data from an extension study. Fintepla will be launched through a restricted distribution program, called the Fintepla Risk Evaluation and Mitigation Strategy (REMS) Program. The drug is expected to be available through Zogenix's specialty pharmacy partner by the end of July. Price target for ZGNX is $50 and is currently trading between $26 - $28. The Markets Red day in general at 500 points down has created an amazing entry price as of 6-26-20. I see this at $36 by Monday.